Bionic Buzz® got to interview Jan Enemaerke, Fluo Labs’ Chief Technology Officer and Co-Founder as part of CES 2021. Fluo Labs, a medical device company on a mission to improve the quality of life for millions of allergy sufferers, today unveiled Flō, a breakthrough device that promises to dramatically improve the way people manage Allergic Rhinitis (AR) — more commonly known as hay fever. With a successful clinical trial under its belt, the working prototype treats AR by using light therapy to inhibit the release of histamines and reduce inflammation – effectively acting as a natural antihistamine.
The new device is affordable, easy-to-use, drug-free and provides rapid relief with no known side effects. Created by a team of experts in the fields of light therapeutics, antihistamines, and nasal steroids, Flō is the result of more than 15 years of cutting-edge research, preclinical and clinical development. Fluo Labs has two additional clinical trials planned and is pursuing FDA approval for the use of Flō as an OTC device. Flō is expected to be available for purchase in late 2021.
How It Works
Flō uses a patented light delivery system of safe light that defends the nose against allergens. Fluo Labs’ scientists have identified the optimal therapeutic window – that precise balance of wavelength, dosage, power and pulse structure – that can effectively inhibit the release of histamines while also working to reduce inflammation. This means that the therapeutic light emitted by the Flō device works as a natural antihistamine that has no known side effects.
The Flō allergy treatment takes less than 20 seconds. To use, simply:
- Hold the Flō up to your nostril
- Click the button for 10 seconds of light therapy
- Repeat in the other nostril
- Repeat steps 1-3 as needed once or twice a day.
Clinical Trials
Fluo Labs conducted an IRB-sanctioned pilot study to evaluate the effectiveness and safety of the first version of the Flō device in reducing symptoms of ragweed allergic rhinitis. The study yielded a 31% improvement in the Total Nasal Symptom Score (TNSS) over baseline. The TNSS score measures congestion, itching, runny nose and sneezing and compares results over a 14-day period to a baseline. TNSS is the gold standard in allergy tests. The results from the Fluo Labs pilot study were significant and superior to what is generally achieved with antihistamines, with the added benefit of no known side effects. Fluo Labs currently has two clinical trials planned in 2021.
Consumers who are interested in purchasing the Flō medical device can sign up for the wait list at: https://www.fluolabs.care/join-the-waitlist.
About Fluo Labs
Fluo Labs is a medical device company on a mission to improve the quality of life for millions of allergy sufferers. Fluo Labs’ founders have decades of industry experience in the development of cutting-edge, light-based medical devices and extensive experience in multiple pharma and biotech therapeutic areas including virology, rhinitis drug therapies and light therapeutics. It’s first product, Flō, allows people to treat the symptoms of allergic rhinitis through a natural, clean, over-the-counter remedy. To learn more, visit:https://www.fluolabs.care/.
